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cell line A549
ABSTRACT 
Introduction: Multidrug resistance of non-small cell lung cancer cells is associated with a high percentage 
of therapeutic failures. The aim of this study was to assess the ability of solid lipid nanoparticles as a 
transporter of the conventionally used cytostatic (5-fluorouracil) to overcome the resistance of A549 cells.
Material and methods: MTT assay was used to assess the differences in viability of cells treated with 
5-fluorouracil alone or in combination with different types of solid lipid nanoparticles. Type of cell death 
and distribution of cell cycle phases were evaluated using flow cytometry. 
Results: The use of nanoparticles as a 5-fluorouracil transporter reduced the viability of A549 cells to a 
greater extent than the cytostatic alone. This was mainly due to the increase in apoptosis, but also necrosis
and cell cycle arrest.
Conclusion: Our results indicate the great potential of nanotechnology in the treatment of non-small cell
lung cancer. By using nanoparticles, it is possible to sensitise tumour cells to cytostatics to which they
are normally resistant. In addition, literature data confirm the safety of solid lipid nanoparticle application. 
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Introduction
In spite of many available treatment methods, non-
small cell lung cancer (NSCLC) remains a serious prob-
lem of world health care. It accounts for about 85% of 
all lung cancer cases, and in terms of incidence it is the 
first among men and the second among women. This 
is mainly caused by factors such as difficulties in early 
diagnosis, its high invasiveness, but also resistance to 
most of the currently available chemotherapeutic agents 
[1]. It drives the search for new, more effective methods of 
therapy for this type of cancer. One promising approach 
is to overcome NSCLC resistance by administering com-
monly used cytostatics in combination with nanoparticles.
Although nanotechnology is a relatively new branch 
of science, its potential application in the field of bio-
technology are remarkable. Intensive research on their 
use in the context of sensing even small amounts of 
substances in analytics, diagnostics of diseases, or 
transport of substances into the cells is underway. It 
was noticed that nanoparticles had sizes similar to 
many of the body’s biomolecules, such as receptors, 
antibodies, or proteins. Due to their properties, they 
can easily penetrate the cells but can also be modified 
with other molecules [2]. Nanotechnology gives the 
possibility to link nanoparticles and nanomaterials 
with currently used cytostatics, which may be helpful 
in more efficient transport of drugs to cells, but also 
constitute the basis of therapy targeted only on cancer 
cells [3]. In recent years, cancer nanotechnology has 
developed significantly. Different types of nanoparticles 
have been combined with conventionally used drugs 
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such as doxorubicin [4], paclitaxel [5], or bleomycin 
[6] in in vitro studies, resulting in better response than
administration of the drugs alone. Moreover, the safety
and efficacy of their use was also confirmed in in vivo
studies [5].
One type of nanoparticles was created for the first 
time in 1990: Solid Lipid Nanoparticles (SLN). They re-
veal advantages such as high biocompatibility and low 
toxicity. Also, in the case of SLN, safety of their use has 
been demonstrated in both in vitro and in vivo studies 
[7,8]. Moreover, they can be used via various routes 
of administration such as parenteral, oral, pulmonary, 
or rectal. However, their relatively low drug loading 
capacity remains a significant problem [9]. For these 
reasons, studies on SLN modifications with the aim of 
enhaning their properties are becoming more and more 
popular. One of the tested solutions is the use of SLN 
modified with a natural polysaccharide – chitosan [9]. 
This naturally occurring polymer also does not exhibit 
toxicity while regulating the release and increasing the 
biocompatibility of hydrophobic molecules. 
One of the widely used cytostatics is 5-fluorouracil 
(5-FU). The compound is commonly used for head, 
neck, gastrointestinal, and breast cancers. Because 
of the resistance of NSCLC in this cancer type it is 
mainly applied in combined therapies, for example with 
cisplatin [10]. Furthermore, some studies indicate that 
its application often causes wide range of side effects 
[11]. The use of 5-FU in combination with nanoparticles 
potentially reduces both the resistance of the cancer 
cell lines and also limits the intensity of side effects 
by lowering the dose of the drug necessary to induce 
the effect. 
The aim of our study was to elucidate whether the 
combination of 5-FU together with different SLN variants 
affects the resistance of the A549 non-small cell lung 
carcinoma cell line. 
Material and methods
Cell culture
Non-small cell cancer cell line A549 was kindly 
provided by P. Kopiński, Ph.D. (Department of Gene 
Therapy, Ludwik Rydygier Collegium Medicum in 
Bydgoszcz, Nicolaus Copernicus University in Toruń, 
Poland) and cultured under standard conditions 
(37°C, 5% CO2, humidified atmosphere) in Dulbecco’s 
modified Eagle’s medium (DMEM; Sigma-Aldrich, St., 
Louis, MO, USA) with the addition of 10% foetal bovine 
serum (FBS; Sigma-Aldrich, St., Louis, MO, USA) and 
antibiotics (50 μg/ml of gentamycin; Sigma-Aldrich, St., 
Louis, MO, USA). The cells were grown as a monolayer 
in 6- or 12-well plates or culture flasks, depending on 
the experiment. After reaching 70–80% confluence the 
cells were treated for 24 h with nanoparticles containing 
5-fluorouracil (5-FU; Sigma-Aldrich, St., Louis, MO, USA) 
to obtain 0.5, 1, 1.5, 2, and 4 mM concentrations of the 
drug. Additionally, two types of control cells were applied. 
The first were cells cultured in clean culture medium, while 
the second comprised cells treated with empty nanopar-
ticles (without 5-FU addition) at the same concentration 
as for the study group. During the time of experiment 
regular tests for mycoplasma infections based on rapid 
uptake of the DAPI (Sigma-Aldrich) by cellular DNA were 
conducted and found to be negative [12].
Nanoparticles preparation 
The nanoparticles were prepared on the basis of 
the modified protocol presented by Xiao-Ying et al. [9]. 
In brief, monostearin (MON; Sigma-Aldrich, St., Louis, 
MO, USA) was dissolved in DMSO at 75°C, while chitosan 
oligosaccharide (CSO; Sigma-Aldrich) was dissolved in 
water at room temperature (RT). The monostearin was 
then mixed with 5-FU in DMSO and heated again. The 
resulting solution was suspended in water (MON, SLN), 
water with chitosan (CH, SLN modified with chitosan), or 
water with chitosan oligosaccharide and various amounts 
of glutaraldehyde (1 µM GA or 3 µM GA, cross-linked 
SLN modified with chitosan oligosaccharide). Next, the 
nanoparticle solutions were mixed intensively for six hours 
and frozen overnight after acidification with 1M HCl. The 
next day, the nanoparticle solutions were thawed and 
centrifuged (15,000 rpm, 45 min.). The resulting precipi-
tate was washed with phosphate-buffered saline (PBS), 
centrifuged again, and resuspended in PBS. The control 
nanoparticles were prepared according to the same proto-
col but with the addition of DMSO instead of 5-FU solution. 
The assessment of encapsulation efficiency and 
drug loading capacity 
In the first stage, a standard curve for 5-FU at 
a wavelength of 267 nm was obtained by measuring the 
absorbance of increasing concentrations of cytostatic. 
From the prepared samples 100 µl was taken and 
added to 900 µl of DMSO. The samples were heated 
for 45 min at 37°C and centrifuged. The absorbance of 
the supernatant was measured by a spectrophotometer 
(Spectra Academy, K-MAC, Korea). The 5-FU content 
in the supernatant was determined from the standard 
curve. Drug loading (DL) and encapsulation efficiency 
(EE) were calculated based on the following formulas: 
EE=(W5_FU – WS) × 100%W5_FU
DL=(         W5_FU – WS        ) × 100%W5_FU – WS + WM + WCSO
W5-FU  — theoretical 5-FU concentration 
WS  — measured 5-FU concentration in the supernatant 




WCSO  — concentration of chitosan
MTT assay
The cell viability was assessed using MTT assay. 
For this purpose, A549 was grown in 12-well plates 
and treated with selected concentrations of 5-FU load-
ed SLN or 5-FU alone (0.5, 1, 1.5, 2, 4 mM) for 24 h. 
Then, the 5 mg/ml MTT solution (Sigma-Aldrich) was 
prepared and mixed with DMEM without phenol red 
(Lonza, Basel, Switzerland) at the ratio of 1:9. Next, the 
solution was added to the cells for 3 h. After this time, 
the resultant purple formazan crystals were dissolved 
in isopropanol (10 min, 37°C; Avantor, Gliwice, Poland) 
and centrifuged at 13,000 RPM for 2 min. The intensity 
of the violet colour of the samples corresponding to the 
cell viability was measured with a spectrophotometer 
(Spectra Academy) at 570 nm wavelength. The results 
obtained for appropriate controls were assumed as 
100%. Moreover, on the basis of obtained data the half 
maximal inhibitory concentration (IC50) was estimated 
using CompuSyn software [13].
Cell death analysis
In order to evaluate the mechanism of cell death 
underlying the reduction of cell viability, double staining 
with annexin V and propidium iodide (AV, PI; Invitro-
gen, Life Technologies, Thermo Fisher Scientific, Inc., 
Waltham, MA, USA) was used. The obtained results 
allowed the distinction of live (AV-/PI-), early apoptotic 
(AV+/PI-), late apoptotic (AV+/PI+), and necrotic 
(AV-/PI+) cell populations. The whole procedure was 
performed according to the manufacturer’s protocol. 
Briefly, the A549 cells were cultured on six-well plates 
with the addition of 5-FU loaded SLN or 5-FU alone 
for 24 h. Next, the cells were trypsinised, centrifuged, 
resuspended in 100 µl of Annexin Binding Buffer (ABB; 
Invitrogen/Life Technologies), and then 5 µl of Annexin 
V Alexa Fluor 488 was added for 20 min. Then, cells 
were centrifuged again, resuspended in 100 µl of ABB, 
and incubated with 1 µl of PI for 3 min. The obtained 
data were analysed using a Guava easyCyte 6HT-2L 
Benchtop Flow Cytometer (Merck Milipore, Burlington, 
MA, USA) and FlowJo vX0.7 software (FlowJo LLC, 
Ashand, OR, USA).
Cell cycle assessment
The distribution of the cell cycle phases of cells 
treated with 5-FU loaded SLN and 5-FU alone was 
evaluated using a flow cytometer and Tali Cell Cycle Kit 
(Invitrogen/Life Technologies, Thermo Fisher Scientific, 
Inc., Waltham, MA, USA) according to the manufac-
turer’s instructions. After 24 h of treatment the cells 
were trypsinised, centrifuged, fixed with ice-cold 70% 
ethanol, and refrigerated overnight. The next day, the 
cells were centrifuged, washed with PBS, centrifuged 
again, resuspended in the Tali Cell Cycle Solution, and 
incubated for 30 min. The results were analysed using 
a Guava easyCyte 6HT-2L Benchtop Flow Cytometer 
(Merck Milipore). The percentage of cells in each cell 
cycle phase was assessed by FlowJo vX0.7 software 
(FlowJo LLC).
Statistical analysis 
The results were considered significant when 
P < 0.05. The statistical analysis was carried out using 
GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, 
CA, USA). The MTT assay results were analysed with the 
nonparametric Wilcoxon test assuming the control as 
100%. The cell death was assessed using Kruskal-Wallis 
test, and the cell cycle was evaluated by two-way ANO-
VA test. Statistically significant differences are marked 
with an asterisk.
Results
Encapsulation efficiency and drug-loading 
capacity
In order to assess encapsulation efficiency and 
drug-loading capacity spectrophotometric measure-
ments at a wavelength of 267 nm were conducted and 
then aligned to a standard curve. The obtained values 
were similar for all SLN modifications used. The mean 
value calculated from five independent measurements 
of encapsulation efficiency was 95.83% for unmodified 
SLN (MON), 91.77% for chitosan-modified nanoparticles 
(CSO), 94.79% for chitosan-modified nanoparticles with 
1 µM glutaraldehyde (1 GA), and 94.81% for those with 
the addition of 3 µM glutaraldehyde (3 GA). In turn, the 
drug-loading capacity, determined in a similar way, 
reached 75.83% (MON), 71.82% (CSO), 74.82% (1 GA), 
and 74.83% (3 GA), respectively. All of the mentioned 
results are shown in Figure 1.
MTT assay 
In order to evaluate the effect of 5-FU alone and 
the cytostatic encapsulated in the nanoparticles 
MTT assay was performed. The results are shown in 
Figure 2. In all cases, a dose-dependent decrease 
in the number of viable cells was observed. For 5-FU 
after 24-h incubation with cytostatic, values of 80.37%, 
69.54%, 67.26%, 54.17%, and 44.94% were obtained 
for subsequent doses of 0.5, 1, 1.5, 2, and 4 µM 5-FU, 
respectively (Fig. 2A). In the case of unmodified SLN, the 
number of living cells was significantly reduced only in 
the highest dose in comparison to 5-FU alone, and the 
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Figure 1. Encapsulation efficiency and drug-loading capacity. A. A standard curve determining the dependence of 
absorbance on the concentration of 5-FU measured at a wavelength of 266 nm used to assess the EE% (encapsulation 
efficiency) and DL% (drug-loading capacity) of types of nanoparticles used. B. The encapsulation efficiency (EE%) and 
drug-loading capacity (DL%). The mean value calculated from five independent measurements of encapsulation efficiency 
for unmodified SLN (MON), chitosan-modified nanoparticles (CSO), chitosan-modified nanoparticles cross-linked with 
1 µM glutaraldehyde (1 GA), and chitosan-modified nanoparticles cross-linked with 3 µM glutaraldehyde (3 GA)
Figure 2. Analysis of A549 cell viability. The MTT assay was performed to evaluate the effect of 5-FU alone and the 
cytostatic encapsulated in the nanoparticles after 24 h. A549 cells were treated with different concentrations (0.5, 1, 
1.5, 2, 4 mM) of: A) 5-FU; B) 5-FU-loaded unmodified SLN (5-FU + MON); C) 5-FU-loaded chitosan-modified SLNs 
(5-FU + CSO); D) 5-FU-loaded chitosan-modified SLNs crosslinked with 1 µM glutaraldehyde (5-FU + 1 GA); and E) 
5-FU-loaded chitosan-modified SLNs crosslinked with 3 µM glutaraldehyde (5-FU + 3 GA). The data were represented
by mean ± SD.“*” p < 0.05 vs. untreated cells (CTRL)
percentage for all doses amounted to 81.18%, 82.28%, 
73.92%, 58.63%, and 36.47%, respectively (Fig. 2B). 
For chitosan-modified nanoparticles, the limiting effect 
on the A549 line resistance to 5-FU was not observed 
as the percentage of viable cells was 79.45%, 76.51%, 
72.38%, 67.0%, and 57.28% for successively increasing 
doses (Fig. 2C). A similar situation was noted in the 
case of nanoparticles modified with chitosan with the 
addition of glutaraldehyde as a cross-linking agent. 
At a lower concentration of glutaraldehyde, the differ-
ence between the effectiveness of nanoparticles and 
5-FU was not confirmed, and the cell viability reached
85.66%, 81.56%, 71.14%, 61.16%, and 44.71% (Fig. 2D). 
In turn, the use of higher glutaraldehyde concentration
at the highest doses of 5-FU (2 and 4 µM) resulted
in a decrease in viability to a greater degree than for
5-FU alone; the percentage of living cells was 86.31%,




Figure 3. Analysis of cell death. The double staining of annexin V (AV) and propidium iodide (PI) was used to evaluate 
the type of cell death. A549 cells were treated with 2 and 4 mM of 5-FU, 5-FU-loaded unmodified SLNs (5-FU + MON), 
and 5-FU loaded chitosan-modified SLNs crosslinked with 3 µM glutaraldehyde (5-FU + 3 GA). A, E, I – the percentage 
of live cells (AV-/PI-); B, F, J – the percentage of early apoptotic cells (AV+/PI-); C, G, K – the percentage of late apoptotic 
cells (AV+/PI+); D, H, L – the percentage of necrotic cells (AV-/PI+). The data were represented by mean ± SD. “*” 
p < 0.05 vs. untreated cells (CTRL)
and 4 µM doses of 5-FU, respectively, in comparison 
to control (Fig. 2E). At the same time, there was no 
significant effect of the nanoparticles themselves on cell 
survival, which confirms the safety of their use. Because 
the most promising results were obtained for only two 
SLN types – unmodified SLN and chitosan-modified 
SLN cross-linked with 3 µM GA linked with 2 and 4 µM 
doses of 5-FU – the study group in further experiments 
was limited only to them. 
Cell death analysis
In order to elucidate the effect of 5-FU and the cy-
tostatic encapsulated in the SLN, double staining with 
Annexin V and propidium iodide was performed. The re-
sults showed that for 5-FU alone the amount of live cells 
dropped from 93.75% in the control to 92.05% for 2 mM 
and 86.11% for 4 mM doses of the compound (Fig. 
3A). The decrease in the percentage of live cells was 
caused mainly by apoptotic cell death; 3.13% (CTRL), 
3.45% (2 mM 5-FU), and 6.37% (4 mM 5-FU) cells were 
identified as early-apoptotic cells, and 2.54% (CTRL), 
3.36% (2 mM 5-FU), and 5.36% (4 mM 5-FU) as late 
apoptotic (Fig. 3B, C). There was also a slight increase 
in the percentage of necrotic cells, from 0.28% (CTRL) to 
0.5% (2 mM 5-FU) and 1.54% (4 mM 5-FU) (Fig. 3D). For 
unmodified SLN, the percentages were, respectively, 
91.27% (CTRL), 87.4% (2 mM), and 85.74% (4 mM) for 
live, 4.04% (CTRL), 4.44% (2 mM), and 6.48% (4 mM) for 
early apoptotic, and 2.79% (CTRL), 4.32% (2 mM), and 
6.11% (4 mM) for late apoptotic cells (Fig. 3E-G). Simi-
larly as for 5-FU alone, the increase in the percentage of 
necrotic cells from 0.58% through 0.78% to 1.21% was 
observed with the increase in the cytostatic dose (Fig. 
3H). However, the biggest differences were observed in 
the case of SLN modified with chitosan and cross-linked 
with 3 µM concentration of glutaraldehyde. Values of 
91. 35%, 89.3%, and 75.9% were obtained for live cells, 
respectively (Fig. 3I). Again, the decrease in cell survival 
was mainly due to an increase in the percentage of
cells, both early (2.58%, 5.04%, 8.16%, respectively)
and late (2.4%, 3.16%, 10.26%, respectively) apoptotic
cells (Fig. 3J, K). Additionally, enhanced necrotic cell
death was observed, which resulted in an increase in
the percentage of this population from 0.88% through
2.8% to 6.44% (Fig. 3L). In all three groups, only values 
obtained for the highest dose (4 mM) were considered
as statistically significant. At the same time, in the case
of cells treated with empty nanoparticles (without the
addition of 5-FU), no significant differences comparing
to the control cells treated with empty nanoparticles
were confirmed (data not shown).
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Figure 4. Analysis of cell cycle. The Tali Cell Cycle Kit was used to analyse the distribution of the cell cycle phases of 
A549 cells treated with 2 and 4 mM of: A) 5-FU ; B) 5-FU-loaded unmodified SLNs (5-FU + MON); and C) 5-FU-loaded 
chitosan-modified SLNs crosslinked with 3 µM glutaraldehyde (5-FU + 3 GA). Figure presenting the percentage of 
A549 cells population in G0/G1, S, and G0/G2 phases. Data represented by mean ± SD. “*” p < 0.05 vs. untreated 
cells (CTRL)
Cell cycle assessment 
Cell cycle phase evaluation was performed using 
flow cytometry. 5-FU alone caused an increase in the 
percentage of cells in the G0/G1 and G2/M phases 
comparing to untreated control with the values as 
follows: 41.33% (CTRL), 50.2% (2 mM 5-FU), and 
51.1% (4 mM, 5-FU) in the G0/G1 phase. In turn, 
for G2/M the values reached 24.77% for control, 
43.63% for 2 mM, and 33.23% for 4 mM. However, 
in the S phase a decrease was observed dropping 
from 25.93% for control cells to 6.13% for 2 mM and 
9.95% for 4 mM doses of the cytostatic. All of the 
described changes were statistically significant (Fig. 
4A). For unmodified SLN loaded with 5-FU the distri-
bution of cell cycle phases was similar as for the 5-FU 
alone. We observed higher percentage of cells in the 
G0/G1 phase, estimated as 36.4% for control, 46.97% 
for 2 mM, and 50.47% for 4 mM doses of 5-FU. In turn, 
for the S phase the reduction in the cell number was 
confirmed from 19.97% for control, 3.22% for 2 mM, 
and 11.03% for 4 mM, in comparison to the control 
cells treated with empty SLN. For the G2/M phase, 
the effect varied between the doses. An increase from 
34.93% to 45.17% was observed for the 2 mM dose, 
while a decrease to 24.42% for 4 mM was confirmed 
(Fig. 4B). The cell cycle phase distribution undergoes 
a significant change in the cells treated with SLN 
modified with chitosan crosslinked with 3GA. The 
number of cells with a DNA level corresponding to 
the G0/G1 phase decreased from 55.6% for control 
to 38.93% for 2 mM and 49.17% for 4 mM of the com-
pound. For the S phase, 13.7% for control, 21.23% for 
2 mM, and 12.5% for 4 mM dose of 5-FU was noted. 
In contrast, 26.43%, 28.8%, and 34.8% were observed 
for cells in the G2/M phase, for control, and increasing 
doses, respectively (Fig. 4C). 
Discussion
Nanotechnology is a promising tool for the develop-
ment of many branches of science. It is also applied in 
the field of medical science. It may be particularly useful in 
the context of oncology. Potentially, nanoparticles may be 
employed not only as a factor increasing the effectiveness 
of therapy but also as a base for targeted therapy. At the 
same time, the increase in effectiveness may be achieved 
in spite of lowering cytostatics doses, which will probably 
limit side effects. It would also be possible to treat cancers 
known to be resistant to certain types of cytostatics. 
5-FU is a relatively well-known and widely used
cytostatic. Unfortunately, some types of tumours are 
resistant to the drug due to the increased expression 
of Bcl-2, Bcl-XL, and Mcl-1 genes, hyperactivity of 
deoxyuridine triphosphatase, abnormal methylation of 
the MLH1 gene or CpG Islands, altered drug influx and 
efflux, and enhanced drug inactivation [14–19]. Studies 
have shown that nanoparticles coated with 5-FU can 
limit some of these effects. The greater efficiency of 
5-FU-loaded nanoparticles relative to the administration 
of the cytostatic alone has been proven in both in vitro
[7] and in vivo [6] studies. This is also consistent with
our results because the solution of empty nanoparticles 
did not cause any changes in cell viability or cell cycle
in comparison to untreated A549 cells.
The method we propose is a combination of 5-FU 
and SLNs. There are several literature reports suggest-
ing a great potential of such a combination [19–21]. Use 
of SLNs has a lot of advantages because, for example, 
they can be loaded with both hydrophobic and hydro-
philic compounds, and their preparation usually does 
not involve any toxic solutions [22]. Moreover, this ap-
proach is relatively easy to apply; however, the stability 
of the obtained nanoparticles is considered to be low 




to enhance the durability of this type of nanoparticles. In 
accordance with our knowledge, this is the first case of 
using SLN prepared by solvent diffusion method with 
chitosan and glutaraldehyde as a crosslinking agent 
in combination with 5-FU. SLNs prepared with this 
method have a negative charge, which, after adding an 
aqueous solution of chitosan, enabled its adsorption on 
the surface of nanoparticles by generating electrostatic 
interactions. Unfortunately, the study of the efficiency 
of encapsulation and the cytotoxic effect on cells of 
the A549 line showed a decrease in comparison to 
unmodified SLN. This is in contrast to the commonly 
obtained result; usually the coating of nanoparticles with 
chitosan increases their stability [9]. This was probably 
caused by the use of chitosan lactate instead of chi-
tosan, and the difference in the chemical properties of 
both molecules. The results obtained indicate that the 
use of chitosan lactate may interfere with 5-FU binding 
by nanoparticles. However, cross-linking nanopar-
ticles modified with chitosan under the influence of 
glutaraldehyde increases their stability. This resulted in 
enhanced encapsulation efficiency and cytotoxic effect 
with growing GA concentration. The same observations 
were made by Xiao-Ying et al., who also confirmed an 
increase in the efficiency of encapsulation due to cross-
linking of SLNs modified with chitosan using GA [9]. The 
results were also confirmed by cell survival analysis, 
which was found to be lower for SLNs cross-linked with 
3µM GA than for any other nanoparticle group. At the 
same time, the demonstrated higher efficiency of SLNs 
modified with chitosan and cross-linked with 3 µM GA 
was not associated with differences in parameters such 
as drug-loading capacity or encapsulation efficiency, as 
they were very similar for all types of nanoparticles used. 
The observed decrease in cell viability was caused 
mainly by apoptosis and cell cycle arrest, and to a lower 
extent also by necrosis. All of these phenomena were 
intensified after treatment with drug entrapped in SLNs 
modified with chitosan and cross-linked with 3 µM GA. 
The increase in the apoptotic cell death in cancer cells 
is one of the most desirable effects of anti-tumour com-
pounds due to the lack of inflammation induction by this 
type of death [23]. Moreover, addition of SNLs changed 
the cell cycle phase distribution especially in the case of 
SLNs modified with chitosan and cross-linked with 3 µM 
GA. Alterations in cell cycle after encapsulation of the 
drug in different types of nanoparticles including SLNs 
were also confirmed by available literature reports [24, 
25]. All of this suggests that the use of modified SLNs 
loaded with 5-FU may be beneficial in the treatment of 
5-FU-resistant non-small cell lung cancer. The next step 
in research should be the assessment of the selective
effect of designed nanoparticles on cancer cells by
comparing them to the impact on normal lung cells.
Conclusion
The obtained data suggest that SLNs modified 
with chitosan and cross-linked with GA may be useful 
in overcoming the resistance of non-small cell lung 
cancer to 5-FU. Additionally, nanoparticles seem to be 
not only an effective but also a safe tool, which requires 
confirmation also on normal cell lines. Furthermore, the 
effectiveness of SLNs may be improved by introduction 
of modifications in their design such as coating with 
additional substances or cross-linking. 
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